Tian, Di
Stoppel, Laura J
Heynen, Arnold J
Lindemann, Lothar
Jaeschke, Georg
Mills, Alea A
Bear, Mark F
Article History
Received: 26 September 2014
Accepted: 3 December 2014
First Online: 12 January 2015
Competing interests
: M.F.B. holds patents on the use of mGluR5 inhibitors for treatment of fragile X and autism. M.F.B. and D.T. have patents pending on use of mGluR5 inhibitors for treatment of 16p11.2 microdeletion. L.L. and G.J. are employees of Roche Pharmaceuticals.